M. Marty

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, S. M. Steinberg, M Blichert-Toft et al. · PubMed · 1998 · 2.2K citations

Medicine, Oncology, Pharmacotherapy +5

Early assessment of a new anticancer drug analogue — are the historical comparisons obsolete? The French experience with pirarubicin

Patrice Herait, N. Poutignat, M. Marty et al. · European Journal of Cancer · 1992 · 47 citations

Medicine, Medicinal Chemistry, Pharmacology +12

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

J.M. Extra, F. Cognetti, D Maranichi et al. · European Journal of Cancer Supplements · 2004 · 21 citations

Medicine, Oncology, Pharmacology +17

Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC)

F Penault–Llorca, Anne Vincent‐Salomon, M-C Mathieu et al. · Journal of Clinical Oncology · 2005 · 19 citations

Medicine, Oncology, Cancer Epidemiology +13

Cowden disease and Lhermitte Duclos disease, markers of breast carcinoma: Report of two patients

A.C. Braud, A. de Rocquancourt, M. Marty et al. · Annals of Oncology · 1999 · 13 citations · Full text

Life Sciences, Genetics, Oncology +16